At the Division of Minimally Invasive Surgery at Tulane Department of Surgery we specialize in Minimally Invasive “Foregut Surgery”. The foregut includes the esophagus, stomach, and upper small intestines, including the duodenum and jejunum.
As defined by the American Foregut Society “The foregut specialist is someone committed to a deep understanding of the pathophysiology, diagnosis and treatment of foregut disease and has expertise in a broad range of therapeutic options individualized to the specific needs of each patient.
For most patients, minimally invasive procedures performed with the da Vinci Surgical System (Robotic Surgery) can offer numerous potential benefits over open-abdominal surgery, including:
- Shorter hospital stay
- Less pain and scarring
- Less risk of wound infections
- Less blood loss
- Faster recovery
- Quicker return to normal activities.
The da Vinci Surgical System can also be used across abroad range of general surgical procedures, including bariatric, esophageal and general surgery. (see Robotic Surgery procedures)
Conditions of the Foregut that can be treated with Minimally Invasive Surgery:
GASTRIC PACEMAKER (Gastric Electrical Stimulator) FOR GASTROPARESIS
Gastroparesis is a chronic debilitating condition characterized by the delay emptying of the stomach after eating. Symptoms include nausea, vomiting, early satiety and abdominal pain—as a result of these symptoms—difficulty for patients to meet their nutritional and caloric needs.
The Enterra® Therapy System is a device that is implanted in the stomach of the patient, and promotes digestion using electrical stimulation. This device has been approved by the United States Food and Drug Administration (FDA) for this specific indication in a limited number of patients. Because the FDA has only approved the device’s use in a very limited number of people, it is considered to be a Humanitarian Use Device and it requires IRB oversight.
The Enterra® Therapy System consists of an implantable neurostimulator (a device similar to a cardiac pacemaker), two intramuscular leads (wires), and an external programmer (computer). Implantation of the device requires 1 hour Laparoscopic/Robotic surgical procedure that takes place under general anesthetic. During surgery, the leads will be positioned with minimally invasive surgery in the middle part of the stomach, then, subcutaneously connected to the neurostimulator to provide electrical stimulation.
Patients generally remain in the hospital overnight after the procedure.
INDICATIONS AND CONTRAINDICATIONS FOR IT USE:
Eligible patients should have drug-refractory Gastroparesis with one of the following etiologies:
- Idiopathic
- Diabetes mellitus
- Post-surgery
PROCEDURES:
- Implant Procedure:
-----Video of the procedure-----
Follow-Up Schedule:
Follow-up visits will be scheduled at one, three, six, and twelve months and then once a year after implantation of the device.
Robotic-Assisted Total esophagectomy/gastrectomy.
Esophagectomy (removal of all or part of the esophagus) is the treatment of choice for esophageal cancer either as a therapy for the cancer itself or as a way to relieve symptoms, especially difficulty swallowing. Surgery for esophageal cancer is technically demanding operation and carries risks. Traditional (open) surgery involves an incision in the abdomen (laparotomy) and an incision on the side of the chest spreading the ribs (thoracotomy). Increasing experience with laparoscopic procedures has lead to its use in the dissection of the esophagus for total esophagectomy. Surgeons at Tulane have extended the applications of the robotic system for the treatment of esophageal cancer and gastric cancer in selected patients decreasing blood loss, postoperative pain, hospital stay and mortality.